Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19,
interim six-month data expected in 4Q19
Collaboration with CureCN projected to dose first patient with combination of ImmTOR + AAV
gene therapy candidate in 2H19
Company raises $33M in gross offering proceeds and $31.3M in net proceeds in 1Q19, cash
runway into 1Q20...
